Piramal Enterprises share price has plunged 4% and is presently trading at Rs 948.6.
Meanwhile, the BSE HEALTHCARE index is at 40,830.6 .
Among the top losers in the BSE HEALTHCARE index today are DR. LAL PATHLABS (down 2.7%) and GLAND PHARMA (down 1.9%).
ERIS LIFESCIENCES (up 2.4%) and FDC (up 1.9%) are among the top gainers today.
Over the last one year, Piramal Enterprises has moved down from Rs 982.5 to Rs 948.6, registering a loss of Rs 33.9 (down 3.4%).
On the other hand, the BSE HEALTHCARE index has moved up from 28,300.0 to 40,830.6, registering a gain of 44.3% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 119.0%), GSK Pharma (up 105.3%) and GRANULES INDIA (up 103.1%).
Must See: These Segments are Witnessing Incredible Growth with Modi's Push
The BSE Sensex is at 79,199.0 (down 0.3%).
The top losers among the BSE Sensex today are JSW Steel (down 1.6%) and Infosys (down 1.5%). The most traded stocks in the BSE Sensex are Tata Steel and Nestle.
In the meantime, NSE Nifty is at 24,230.3 (down 0.3%). Shriram Transport and Infosys are among the top losers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 65,953.5 to 79,199.0, registering a gain of 13,245.5 points (up 20.1%).
Piramal Enterprises net profit grew 170.8% YoY to Rs 1,479 million for the quarter ended March 2024, compared to a loss of Rs 2,090 million a year ago. Net sales rose 16.0% to Rs 24,733 million during the period as against Rs 21,317 million in January-March 2023.
For the year ended March 2024, Piramal Enterprises reported 116.9% decrease in net profit to Rs -16,835 million compared to net profit of Rs 99,686 million during FY23. Revenue of the company grew 12.2% to Rs 100,203 million during FY24.
The current Price to earnings ratio of Piramal Enterprises, based on rolling 12 month earnings, stands at -11.6.
Equitymaster requests your view! Post a comment on "Piramal Enterprises Plunges 4%; BSE HEALTHCARE Index Down 0.0%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!